Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed emesis following anticancer chemotherapy

M G Kris1, F Roila, P H De Mulder

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York, USA.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|June 18, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Deciphering radiological stable disease to immune checkpoint inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

COVID-19 in patients with lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Delayed emesis, occurring 24+ hours after chemotherapy, presents a unique challenge. Effective prevention strategies are crucial for managing this distinct syndrome, especially after strong chemotherapy stimuli.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Delayed emesis is defined as vomiting starting or continuing 24 hours or more post-chemotherapy.
  • This syndrome is more prevalent with strong emetic stimuli or inadequately controlled acute vomiting.
  • The underlying pathophysiology of delayed emesis differs from acute emesis.

Framework:

  • Review of clinical trials focused on preventing delayed nausea and vomiting.
  • Analysis of treatment protocols and patient outcomes.
  • Exploration of the distinct pathophysiological mechanisms involved.

Implementation:

  • Presentation of findings from clinical trials on delayed emesis prevention.
  • Discussion of evidence-based strategies for managing delayed nausea and vomiting.

Related Experiment Videos

  • Evaluation of the efficacy of various antiemetic regimens.

    • Implications:

    • Improved patient management and quality of life during chemotherapy.
    • Potential for new therapeutic guidelines for delayed emesis.
    • Enhanced understanding of chemotherapy-induced nausea and vomiting (CINV) pathophysiology.